Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Other Financing Activities
Financing cash flows not reported separately.
Inogen, Inc.NASDAQ: INGN
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities declines year over year
Q1 FY2026 other financing activities of $622K (cash outflow) fell 80.9% year over year, behind the -73.4% change in trailing-twelve-month other financing activities. Sequentially, it rose 232.6% from the prior quarter. Over 3 fiscal years it compounded at +43.4% a year.
Context
- Other financing activities amounted to 1.1% of revenue in FY2025, up 1.0 pp from a year earlier.
- Other financing activities grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -80.9% toward the trailing-twelve-month pace of -73.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (4M) USD
- Year-over-year change
- -632.4%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4M) | -632.4% |
| FY2024 | 2024-12-31 | (546K) | -5.4% |
| FY2023 | 2023-12-31 | (518K) | +61.8% |
| FY2022 | 2022-12-31 | (1.36M) | -109.4% |
| FY2021 | 2021-12-31 | (647K) | — |
Other Financing Activities vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 other financing activities of $873K is the 5th largest of the 11 companies compared; the peer median is $4.93K.
- Its year-over-year change of -73.4% is the 6th highest of 9, against a peer median of -44.3%.
- Other financing activities amounts to 0.2% of revenue for INGN, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $144.9M | — | — | 268.9% | |
| LTM Dec 2025 | $5.82M | +10455.5% | — | 44.7% | |
| LTM Mar 2026 | $2.05M | -72.7% | — | 21.4% | |
| LTM Mar 2026 | $1.47M | -15.9% | — | 1.0% | |
| LTM Mar 2026 | $873K | -73.4% | +43.4% | 0.2% | |
| LTM Mar 2026 | $371K | +100.4% | — | 60.0% | |
| LTM Mar 2026 | $118K | -101.0% | — | 0.3% | |
| LTM Mar 2026 | $5K | +101.6% | — | 0.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $4.86K | -81.2% | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding INGN) | $4.93K | -44.3% | — | 1.0% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| Deferred Income Tax | 14.44M | 0 | (251K) | (1.15M) | (1.1M) |
| Stock-Based Compensation | 10.94M | 12.28M | 7.43M | 7.4M | 8.01M |
| Change in Working Capital | (20.07M) | (44.72M) | 14.27M | (4.39M) | (26.91M) |
| Accounts Receivables | (5.42M) | (51.62M) | 11.13M | (5.07M) | (14.62M) |
| Inventory | (10.78M) | (5.6M) | 7.88M | (3.54M) | (3.21M) |
| Accounts Payables | (6.48M) | 6.76M | (9.18M) | (3.41M) | 5.6M |
| Other Working Capital | 2.61M | 5.74M | 4.44M | 7.63M | (14.68M) |
| Other Non-Cash Items | 3.02M | 55.16M | 59.62M | 18.94M | 10.87M |
| Operating Cash Flow | 23.63M | (37.53M) | (3.23M) | 5.91M | (11.22M) |
| Capital Expenditures | (23.94M) | (21.22M) | (26.52M) | (17.09M) | (10.38M) |
| Acquisitions (Net) | 153K | 331K | (29.44M) | 0 | 0 |
| Purchases of Investments | (9.99M) | 0 | (26.87M) | (32.66M) | (29.83M) |
| Sales of Investments | 19.26M | 10.01M | 24M | 35.5M | 14M |
| Other Investing Activities | 0 | 0 | 0 | (1.82M) | 0 |
| Investing Cash Flow | (14.65M) | (10.88M) | (59.32M) | (13.98M) | (26.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.65M | 1.74M | 1.48M | 811K | 28.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (647K) | (1.36M) | (518K) | (546K) | (4M) |
| Financing Cash Flow | 15M | 380K | 960K | 265K | 24.18M |
| Effect of Forex Changes | (426K) | (481K) | 67K | (281K) | 846K |
| Net Change in Cash | 23.56M | (48.51M) | (61.52M) | (8.08M) | (12.4M) |
| Free Cash Flow | (302K) | (58.75M) | (29.75M) | (11.18M) | (21.6M) |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.